Targeting IL-23 in psoriasis: current perspectives
Christina Fotiadou, Elizabeth Lazaridou, Eleni Sotiriou, Demetrios Ioannides First Department of Dermatology and Venereology, Aristotle University Medical School, Thessaloniki, Greece Abstract: The recent advances in the understanding of psoriasis pathogenesis have clarifi...
Guardado en:
Autores principales: | Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c6d38008c9c84fdcac40012401ac9465 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck KM, et al.
Publicado: (2018) -
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018) -
Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
por: el Hayderi L, et al.
Publicado: (2016) -
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon S, et al.
Publicado: (2017) -
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Yuliya Lytvyn, PhD, et al.
Publicado: (2022)